4D Molecular Therapeutics
FDMT
12.59
+0.03
+0.24%
4D Molecular Therapeutics
US · FDMT
#3519 by market cap
Listed 2020
12.59
+0.03
+0.24%
Live - 5344 symbols - heartbeat 30s ago
· 2026-10-08 08:05
Pre-market
12.00
-4.69%
After-hours
12.59
0.00%
- Market cap
- 695.52M
- P/E (TTM)i
- -4.79
- P/Bi
- 1.71
- EPSi
- -2.42
- Div yieldi
- 0.00%
- 52W posi
- 56%
Reader sentiment
Are you bullish or bearish on FDMT?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 9 analysts
Buy
Avg price target
30.43 +141.7%
Price target rangecurrent 12.59
Low23.00
Avg30.43
High36.00
Buy 89%
Hold 11%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-06 | Chardan Capital | -- | BUY | 25.00 |
| 2026-09-28 | BofA Securities | -- | BUY | 33.00 |
| 2026-09-28 | Morgan Stanley | -- | HOLD | -- |
| 2026-09-21 | Cantor Fitzgerald | -- | BUY | -- |
| 2026-09-11 | Barclays | -- | BUY | 28.00 |
| 2026-08-17 | Morgan Stanley | -- | HOLD | -- |
| 2026-08-14 | BofA Securities | -- | BUY | -- |
| 2026-08-14 | Morgan Stanley | -- | HOLD | -- |
| 2026-08-14 | H.C. Wainwright | -- | BUY | 36.00 |
| 2026-08-14 | RBC Capital | -- | BUY | 35.00 |
| 2026-07-20 | BofA Securities | -- | BUY | 29.00 |
| 2026-07-20 | Evercore | -- | BUY | 23.00 |
| 2026-07-20 | Goldman Sachs | -- | BUY | 33.00 |
| 2026-07-20 | H.C. Wainwright | -- | BUY | 36.00 |
| 2026-06-30 | H.C. Wainwright | -- | BUY | 36.00 |
| 2026-06-29 | Morgan Stanley | -- | HOLD | -- |
| 2026-05-11 | H.C. Wainwright | -- | BUY | 36.00 |
| 2026-05-08 | Chardan Capital | -- | BUY | 26.00 |
| 2026-05-08 | BofA Securities | -- | BUY | 29.00 |
| 2026-05-08 | Goldman Sachs | -- | BUY | 33.00 |
| 2026-05-07 | RBC Capital | -- | BUY | 35.00 |
| 2026-04-13 | Evercore | -- | BUY | 23.00 |
| 2026-03-30 | Jefferies | -- | BUY | 21.00 |
| 2026-03-20 | H.C. Wainwright | -- | BUY | 36.00 |
| 2026-03-19 | Goldman Sachs | -- | BUY | 38.00 |
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Improving
2
■ Upgrades■ Downgrades
- 2 upgrades vs 0 downgrades among tracked analyst rating changes.
- Most recent: Cantor Fitzgerald moved from Hold to Buy on 2026-09-21.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-09-21 | Cantor Fitzgerald | HOLD → BUY | -- |
| 2025-11-06 | Morgan Stanley | SELL → HOLD | 16.00 |
Quote time 2026-10-08 08:05:41 · For reference only, not investment advice and not tailored to your situation.